Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Trastuzumab rezetecan |
Synonyms | |
Therapy Description |
Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody linked to the camptothecin derivative rezetecan, which potentially induces DNA damage and apoptosis in ERBB2 (HER2)-expressing tumor cells and inhibits tumor growth (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): LB031). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trastuzumab rezetecan | SHR A1811|SHRA1811|SHR-A1811 | HER2 (ERBB2) Antibody 72 HER2 (ERBB2) Antibody-Drug Conjugate 27 | Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody linked to the camptothecin derivative rezetecan, which potentially induces DNA damage and apoptosis in ERBB2 (HER2)-expressing tumor cells and inhibits tumor growth (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): LB031). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04446260 | Phase I | Trastuzumab rezetecan | A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors | Recruiting | USA | AUS | 3 |